Modupe Idowu MD
Clotting Disorder, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias
Associate Professor, Division of Hematology, Dept of Internal Medicine, University of Texas Medical School, Houston
Join to view full profile
6400 Fannin StSte 2900Houston, TX 77030
Phone+1 713-704-3961
Fax+1 713-704-3150
Dr. Idowu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of FloridaFellowship, Hematology and Medical Oncology, 2008 - 2010
Texas Tech University Health Sciences Center at LubbockResidency, Internal Medicine, 2005 - 2008- Texas Tech University Health Sciences Center School of MedicineClass of 2005
Certifications & Licensure
TX State Medical License 2007 - 2027
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealtheLife and FirstNet, Cerner Corporation, 2015-2016
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2015-2016
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2016
Clinical Trials
- Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
- Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE) Start of enrollment: 2015 Oct 12
Publications & Presentations
PubMed
- 1 citationsImpact of Social Vulnerability Index on Multiple Myeloma Mortality.Jia Yi Tan, Boon Jian San, Tze Ern Ong, Yong Hao Yeo, Modupe Idowu
Oncology. 2026-01-01 - Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series.Sami Joudeh, Darayon Moore, Jamal Hasoon, Christopher L Robinson, Modupe Idowu
Orthopedic Reviews. 2026-01-01 - 7 citationsSafety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein
The Lancet. Haematology. 2025-01-01
Press Mentions
Cures for Sickle Cell Disease Arrive After a Painful JourneyOctober 1st, 2024
High Risks and High Costs for Young BloodSeptember 3rd, 2019
UT Physicians Comprehensive Sickle Cell CenterJanuary 14th, 2019
Grant Support
- Tailoring Depression Screening for Sickle Cell Disease: A Novel Approach to Mental Health Care.UNIVERSITY OF HOUSTON2026–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
